These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33316279)

  • 1. Methylnaltrexone crosses the blood-brain barrier and attenuates centrally-mediated behavioral effects of morphine and oxycodone in mice.
    Walentiny DM; Komla E; Moisa LT; Mustafa MA; Poklis JL; Akbarali HI; Beardsley PM
    Neuropharmacology; 2021 Mar; 185():108437. PubMed ID: 33316279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of peripheral opioid receptors by methylnaltrexone does not prevent morphine tolerance in rats.
    Blomqvist KJ; Dudek KA; Viisanen H; Mätlik K; Ahlström FHG; Laitila J; Kalso EA; Rauhala PV; Lilius TO
    J Neurosci Res; 2022 Jan; 100(1):329-338. PubMed ID: 32459013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine.
    Boscan P; Van Hoogmoed LM; Pypendop BH; Farver TB; Snyder JR
    Am J Vet Res; 2006 Jun; 67(6):998-1004. PubMed ID: 16740093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs.
    Foss JF; Bass AS; Goldberg LI
    J Clin Pharmacol; 1993 Aug; 33(8):747-51. PubMed ID: 8408737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of morphine and methylnaltrexone on gastrointestinal pain in healthy male participants.
    Brokjaer A; Olesen AE; Christrup LL; Dahan A; Drewes AM
    Neurogastroenterol Motil; 2015 May; 27(5):693-704. PubMed ID: 25810023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.
    Singleton PA; Moreno-Vinasco L; Sammani S; Wanderling SL; Moss J; Garcia JG
    Am J Respir Cell Mol Biol; 2007 Aug; 37(2):222-31. PubMed ID: 17395891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the potential role of methylnaltrexone in opioid bowel dysfunction.
    Foss JF
    Am J Surg; 2001 Nov; 182(5A Suppl):19S-26S. PubMed ID: 11755893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response.
    Amin HM; Sopchak AM; Foss JF; Esposito BF; Roizen MF; Camporesi EM
    Anesth Analg; 1994 Apr; 78(4):701-5. PubMed ID: 8135389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice.
    Shen KF; Crain SM
    Brain Res; 1997 May; 757(2):176-90. PubMed ID: 9200746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys.
    Bowen CA; Fischer BD; Mello NK; Negus SS
    J Pharmacol Exp Ther; 2002 Jul; 302(1):264-73. PubMed ID: 12065726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.
    Crain SM; Shen KF
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10540-4. PubMed ID: 7479836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers.
    Zacny JP; Wroblewski K; Coalson DW
    Psychopharmacology (Berl); 2015 Jan; 232(1):63-73. PubMed ID: 24871705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
    Largent-Milnes TM; Guo W; Wang HY; Burns LH; Vanderah TW
    J Pain; 2008 Aug; 9(8):700-13. PubMed ID: 18468954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
    Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
    Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antinociceptive effect of oxycodone in diabetic mice.
    Nozaki C; Saitoh A; Tamura N; Kamei J
    Eur J Pharmacol; 2005 Nov; 524(1-3):75-9. PubMed ID: 16256106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity.
    Raleigh MD; Accetturo C; Pravetoni M
    J Pharmacol Exp Ther; 2020 Sep; 374(3):392-403. PubMed ID: 32586850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pharmacokinetics of Subcutaneous Methylnaltrexone Bromide in Rhesus Macaques (
    Jepkes S; Josee-Lemoy M; Knych H; de Lucena T; Ardeshir A; Stockinger DE
    J Am Assoc Lab Anim Sci; 2023 May; 62(3):260-266. PubMed ID: 37080736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid partial agonist effects of 3-O-methylnaltrexone in rhesus monkeys.
    Platt DM; Rowlett JK; Izenwasser S; Spealman RD
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1030-9. PubMed ID: 14634035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats.
    Shannon HE; Lutz EA
    Neuropharmacology; 2002 Feb; 42(2):253-61. PubMed ID: 11804622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.